Piplartine attenuates aminoglycoside-induced TRPV1 activity and protects from hearing loss in mice.

ABSTRACT: Hearing loss is a major health concern in our society, affecting more than 400 million people worldwide. Among the causes, aminoglycoside therapy can result in permanent hearing loss in 40% to 60% of patients receiving treatment, and despite these high numbers, no drug for preventing or treating this type of hearing loss has yet been approved by the US Food and Drug Administration. We have previously conducted high-throughput screenings of bioactive compounds, using zebrafish as our discovery platform, and identified piplartine as a potential therapeutic molecule. In the present study, we expanded this work and characterized piplartine's physicochemical and therapeutic properties. We showed that piplartine had a wide therapeutic window and neither induced nephrotoxicity in vivo in zebrafis

SUBMITTER: Zallocchi M 

PROVIDER: S-EPMC11392653 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature